OFK Stock Overview
Develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 3/6 |
| Past Performance | 6/6 |
| Financial Health | 5/6 |
| Dividends | 4/6 |
Orion Oyj Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €44.48 |
| 52 Week High | €49.88 |
| 52 Week Low | €32.01 |
| Beta | 0.36 |
| 11 Month Change | -6.93% |
| 3 Month Change | -4.22% |
| 1 Year Change | 18.68% |
| 33 Year Change | 21.86% |
| 5 Year Change | 12.84% |
| Change since IPO | 222.32% |
Recent News & Updates
Recent updates
Shareholder Returns
| OFK | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -2.5% | -7.5% | -0.5% |
| 1Y | 18.7% | -24.1% | 8.3% |
Return vs Industry: OFK exceeded the German Pharmaceuticals industry which returned -24.1% over the past year.
Return vs Market: OFK exceeded the German Market which returned 8.3% over the past year.
Price Volatility
| OFK volatility | |
|---|---|
| OFK Average Weekly Movement | 3.2% |
| Pharmaceuticals Industry Average Movement | 6.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: OFK has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: OFK's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1917 | 3,867 | Liisa Hurme | www.orion.fi |
Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides prescription drugs and self-care products, which includes Nubeqa for the treatment of prostate cancer; Precedex, Dexdor, and Precedex for human use; Burana for inflammatory pain; Divina series for menopausal symptoms; Trexan for rheumatoid arthritis and cancer; Stalevo, Entacapone, and Comtess/Comtan for Parkinson’s disease; Biosimilars for rheumatoid arthritis and inflammatory bowel diseases; and Simdax for acute decompensated heart failure, as well as Fareston for breast cancer. It also offers Salmeterol/fluticasone Easyhaler, Budesonide/formoterol Easyhaler, Formoterol Easyhaler, Budesonide Easyhaler, Beclomet Easyhaler, and Buventol Easyhaler drugs for the treatment of asthma and chronic obstructive pulmonary disease.
Orion Oyj Fundamentals Summary
| OFK fundamental statistics | |
|---|---|
| Market cap | €6.26b |
| Earnings (TTM) | €331.70m |
| Revenue (TTM) | €1.43b |
18.9x
P/E Ratio4.4x
P/S RatioIs OFK overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| OFK income statement (TTM) | |
|---|---|
| Revenue | €1.43b |
| Cost of Revenue | €573.20m |
| Gross Profit | €856.00m |
| Other Expenses | €524.30m |
| Earnings | €331.70m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 25, 2025
| Earnings per share (EPS) | 2.36 |
| Gross Margin | 59.89% |
| Net Profit Margin | 23.21% |
| Debt/Equity Ratio | 27.8% |
How did OFK perform over the long term?
See historical performance and comparison